Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents (2016 - 2025)

Ocular Therapeutix has reported Cash & Equivalents over the past 13 years, most recently at $737.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $737.1 million for Q4 2025, up 87.98% from a year ago — trailing twelve months through Dec 2025 was $737.1 million (up 87.98% YoY), and the annual figure for FY2025 was $737.1 million, up 87.98%.
  • Cash & Equivalents for Q4 2025 was $737.1 million at Ocular Therapeutix, up from $344.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for OCUL hit a ceiling of $737.1 million in Q4 2025 and a floor of $66.6 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $193.8 million (2021), compared with a mean of $264.2 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 50.49% in 2023 and later surged 590.16% in 2024.
  • Ocular Therapeutix's Cash & Equivalents stood at $164.2 million in 2021, then crashed by 37.68% to $102.3 million in 2022, then skyrocketed by 91.4% to $195.8 million in 2023, then surged by 100.25% to $392.1 million in 2024, then soared by 87.98% to $737.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $737.1 million (Q4 2025), $344.8 million (Q3 2025), and $391.1 million (Q2 2025) per Business Quant data.